Compounds That Inhibit Replication Of Human Immunodeficiency Virus
OwnerJan Balzarini, Anders Vahlne +2inventors
InventorsJan Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
Life of this patent
Estimating the term…
Loading patent…
OwnerJan Balzarini, Anders Vahlne +2inventors
InventorsJan Balzarini, Anders Vahlne, Marita Hogberg, Weimin Tong
Estimating the term…
The present invention relates to the discovery of a novel class of compounds that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compounds. More specifically, it has been found that enzymatically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compounds that inhibit HUV, methods to isolate and synthesize modified glycinamide compounds, and therapeutic compositions comprising these compounds.
-62. (canceled)
A method of inhibiting in-vitro replication of human immunodeficiency virus (HIV) comprising providing an HIV inhibiting amount of a composition comprising as an active ingredient, with or without other active ingredients, a compound of formula N:
A method of inhibiting in-vitro replication of human immunodeficiency virus (HIV) comprising providing an HIV inhibiting amount of a composition that comprises a compound of formula N:
A method of inhibiting replication of human immunodeficiency virus (HIV) comprising:
A method of inhibiting replication of human immunodeficiency virus (HIV) comprising:
Dependencies are inferred from the claim text.